BXQ-350
Newly Diagnosed Metastatic Colorectal Cancer (mCRC)
Key Facts
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a private, clinical-stage biotech advancing BXQ-350, a first-in-class biologic designed to modulate sphingolipid metabolism. Its dual mechanism aims to create an anti-tumor environment by altering key lipid signaling molecules while also demonstrating neuroprotective properties to address chemotherapy-induced peripheral neuropathy. The company has completed enrollment in a Phase 1b/2a trial in first-line metastatic colorectal cancer (mCRC) and a proof-of-concept study in CIPN, positioning it to address significant unmet needs in oncology supportive care.
View full company profileAbout Bexion Pharmaceuticals
Bexion Pharmaceuticals is a private, clinical-stage biotech advancing BXQ-350, a first-in-class biologic designed to modulate sphingolipid metabolism. Its dual mechanism aims to create an anti-tumor environment by altering key lipid signaling molecules while also demonstrating neuroprotective properties to address chemotherapy-induced peripheral neuropathy. The company has completed enrollment in a Phase 1b/2a trial in first-line metastatic colorectal cancer (mCRC) and a proof-of-concept study in CIPN, positioning it to address significant unmet needs in oncology supportive care.
View full company profileAbout Bexion Pharmaceuticals
Bexion Pharmaceuticals is a private, clinical-stage biotech advancing BXQ-350, a first-in-class biologic designed to modulate sphingolipid metabolism. Its dual mechanism aims to create an anti-tumor environment by altering key lipid signaling molecules while also demonstrating neuroprotective properties to address chemotherapy-induced peripheral neuropathy. The company has completed enrollment in a Phase 1b/2a trial in first-line metastatic colorectal cancer (mCRC) and a proof-of-concept study in CIPN, positioning it to address significant unmet needs in oncology supportive care.
View full company profile